You searched for "infections"

2551 results found

Inferior oblique botulinum toxin as a postoperative test

The authors aimed to evaluate the role of inferior oblique (IO) botulinum toxin (BT) injection as a surgical simulator prior to IO myectomy, i.e. preoperative diplopia test using BT. This was a retrospective review in a single centre over a...

Use of reduced volume BT as a treatment option for acute onset comitant esotropia

In this study, the effectiveness and safety of botulinum toxin (BT) for patients with acute acquired comitant esotropia (AACE) and deviation ≤25PD was investigated with comparison of results to conservative prism therapy. Botulinum toxin was undertaken without electromyographic guidance and...

Clinical evaluation of a multifocal aspheric diffractive intraocular lens

This is a multi-centre prospective study involving five different centres in Europe including 52 patients with cataract. The average age was 68.5±10.5 years, 35 females were bilateral implanted with aspheric diffractive multifocal lens implantation of the Tecnis 1-Piece multifocal intraocular...

Navigating an Ophthalmology Lab-Based Research Elective: Reflections and Insights from Johns Hopkins Wilmer Eye Institute

Medical school electives offer valuable opportunities to gain exposure to different healthcare systems and bridge specific gaps in training. While clinical electives are often the primary choice for medical students, research-focused electives also present unique benefits, particularly for those interested...

The 2020 Milgram Experiment

Will ophthalmology recover from COVID-19? Learning Curve columnist Gwyn Samuel Williams shares his thoughts on the developing impact of the pandemic “It’s busy today,” the nurse in green chuckles. “There are six patients I think.” Six. This clinic is designed...

Retinal Vein Occlusions: Evidence-based Management

This reference book is designed to enable an ophthalmologist to make diagnostic and treatment decisions on the basis of the available scientific evidence. This is a very comprehensive book covering all aspects of central retinal vein occlusions including basics, clinical...

Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery

This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...

Effect of anti-VEGF treatment on PED morphology

This retrospective study of 30 eyes assessed the effect of anti-VEGF on morphology of pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD). Thirty eyes of 28 patients with PED were compared to 30 eyes of 30 patients with...

Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema

Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...

PRN Ranibizumab verses continuous aflibercept in UK clinical practice

This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...